CytomX Therapeutics, Inc. (CTMX) Operating income 2016–2025
CytomX Therapeutics, Inc. (CTMX) annual operating income history from SEC filings — each fiscal year as reported.
-$22.4MFY2025 · since FY2016: -$59.6M → -$22.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$22.4M | -189.5% |
| FY2024 | $25.0M | +485.5% |
| FY2023 | -$6.5M | +93.6% |
| FY2022 | -$101.3M | +12.7% |
| FY2021 | -$116.0M | -44.1% |
| FY2020 | -$80.5M | +43.1% |
| FY2019 | -$141.5M | -81.7% |
| FY2018 | -$77.9M | -68.3% |
| FY2017 | -$46.3M | +22.4% |
| FY2016 | -$59.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More CTMX financial trends
CTMX RevenueCTMX Net incomeCTMX Net marginCTMX Gross profitCTMX Gross marginCTMX Operating marginCTMX Operating cash flowCTMX Free cash flowCTMX Capital expendituresCTMX Return on equityCTMX Stock buybacksCTMX Dividends paidCTMX Total assetsCTMX Total liabilitiesCTMX Shareholders’ equityCTMX overview →